相关临床试验
128
8 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1743
进行中（未招募）
3
2.3%
已完成
82
64.1%
Enrolling By Invitation
1
0.8%
尚未招募
4
3.1%
招募中
22
17.2%
暂停
1
0.8%
终止
6
4.7%
Unknown
7
5.5%
撤回
2
1.6%
暂无批准数据
- University of Delaware researchers developed a machine-learning algorithm that identifies hidden EEG abnormalities linked to genetic epilepsy without requiring active seizure capture. - The proof-of-concept study in mice achieved up to 86% accuracy in detecting TSC1 gene variations across two of three mouse strains using baseline brain waves alone. - The team is now transitioning the method into clinical testing on pediatric EEG recordings at Nemours Children's Health, funded by the Delaware Clinical and Translational Research ACCEL Program. - Researchers envision future applications including wearable EEG monitoring and extension to other neurological conditions such as autism and ADHD.
- ZIVO Bioscience has entered into a collaboration with a leading global animal health company to develop immune-boosting compounds derived from proprietary algal cultures for poultry applications. - Two independent studies will focus on coccidiosis and viral diseases, with the partner company providing full funding for trials designed to validate ZIVO's compounds as immune-enhancing biologics. - University of Delaware research identified an optimal formulation of ZIVO's active ingredients that demonstrated slower transmission of low pathogenicity avian influenza virus in poultry. - The collaboration represents a significant expansion of ZIVO's therapeutic applications, potentially addressing major unmet needs across multiple livestock and companion animal species.
- Researchers developed bio-functional hydrogel-coated membranes (HCMs) that significantly reduce T-cell exhaustion during CAR-T manufacturing compared to industry standard TransAct activation methods. - The HCM platform using combinations of anti-CD3, anti-CD28, anti-4-1BB, and anti-OX40 co-stimulatory molecules promotes central memory T-cell phenotypes while maintaining robust activation and proliferation. - CAR-T cells produced using the optimized HCM combination demonstrated superior killing efficacy against target cancer cells, achieving 28% cytolysis compared to 19% with conventional methods.
